Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 52 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Colitis
- Significant unmet need for new effective therapies exists in ulcerative colitis - ELEVATE UC clinical trial sites continue to initiate SAN DIEGO , June 17, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the first subject has been dosed in ELEVATE UC 52, the
View HTML
Toggle Summary Arena Pharmaceuticals to Present at JMP Securities Life Sciences Conference on June 19
SAN DIEGO , June 13, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, will present a corporate update at the JMP Securities Life Sciences Conference on Wednesday, June 19, 2019 , at 1:30 PM
View HTML
Toggle Summary Arena Pharmaceuticals' Presence at Digestive Disease Week (DDW) Reinforces Commitment to the Gastrointestinal Disease Community
- ELEVATE UC Phase 3 global program site initiations - New data for both etrasimod and olorinab SAN DIEGO , May 17, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has initiated sites for its ELEVATE UC Phase 3 global program to evaluate etrasimod 2 mg in
View HTML
Toggle Summary Arena Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO , May 13, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate at the upcoming investor conferences: UBS Global Healthcare Conference on Monday, May 20 , at 8:30 AM EDT in New York City RBC Capital
View HTML
Toggle Summary Arena Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference on April 10
SAN DIEGO , April 3, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, will present a corporate update at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at 12:00 PM
View HTML
Toggle Summary Arena Pharmaceuticals Presented New Phase 2 Data for Etrasimod and Olorinab at the 14th Congress of European Crohn's and Colitis Organisation
SAN DIEGO , March 8, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new Phase 2 data from its investigative drug candidates etrasimod, a next-generation, oral, selective sphingosine 1 phosphate (S1P) receptor modulator in development for the treatment of moderate to
View HTML
Toggle Summary Arena Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference on February 27
SAN DIEGO , Feb. 21, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, will present a corporate update at the 8th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27, 2019
View HTML
Toggle Summary Arena Pharmaceuticals Presents Preclinical and Early Clinical Development Data for Olorinab at Crohn's & Colitis Congress
SAN DIEGO , Feb. 7, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will present preclinical and early clinical development data from its investigative drug candidate olorinab, a peripherally restricted, highly selective, full agonist of the cannabinoid receptor type 2 (CB 2 ) in
View HTML
Toggle Summary Arena Pharmaceuticals Announces Closing of Global License Agreement with United Therapeutics for Ralinepag
SAN DIEGO , Jan. 24, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the closing of the global license agreement with United Therapeutics Corporation (Nasdaq: UTHR) for the Arena-discovered, Phase 3 investigational drug candidate ralinepag, a next-generation, oral,
View HTML
Toggle Summary Arena Pharmaceuticals Reports Positive Long-Term Data from the Open-Label Extension of the Phase 2 OASIS Trial Evaluating Etrasimod for Treatment of Ulcerative Colitis
- Etrasimod demonstrated clinical response and durable, long-term clinical remission - Etrasimod demonstrated favorable long-term safety and tolerability SAN DIEGO , Jan. 7, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced positive data from the open-label extension
View HTML